COMPANY

Voyager Therapeutics

HQ: Lexington, MA source · voyagertherapeutics.com ↗

FDA-cleared device company Clinical Phase 2

Keywords: neurology Alzheimer's disease amyotrophic lateral sclerosis Parkinson's disease Alzheimer s Disease Alzheimer's Disease Huntington Disease VY7523 Intraparenchymal rAAV1 - (mi)RNA HTT

Location: Lexington, MA · source · Oct 14, 2026

Profile checked Oct 10, 2026

3Trials (company is sponsor)

Timeline

Sep 3, 2026 Trial start Phase 1: An Open Label Dose Escalation Study of VY1706 in Participants With Early Alzheimer's Disease source ↗
Mar 3, 2025 Trial start Phase 1/Phase 2: VY7523-102: Randomized, Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study in Participants With Early Alzheimer's Disease source ↗
Jul 30, 2021 Trial start Phase 1: Safety and Tolerability Study With VY-HTT01, in Adults With Early Manifesting Huntington's Disease source ↗

Upcoming milestones

2027-05 (ESTIMATED) · Phase 1/Phase 2 · VY7523-102: Randomized, Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study in Participants With Early Alzheimer's Disease · NCT06874621
Apr 28, 2029 (ESTIMATED) · Phase 1 · An Open Label Dose Escalation Study of VY1706 in Participants With Early Alzheimer's Disease · NCT07764146

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 3

Record	Title	Phase	Status	Start	Primary completion
NCT07764146	An Open Label Dose Escalation Study of VY1706 in Participants With Early Alzheimer's Disease	Phase 1	Recruiting	Sep 3, 2026	Apr 28, 2029 (estimated)
NCT06874621	VY7523-102: Randomized, Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study in Participants With Early Alzheimer's Disease	Phase 1/Phase 2	Active, not recruiting	Mar 3, 2025	2027-05 (estimated)
NCT04885114	Safety and Tolerability Study With VY-HTT01, in Adults With Early Manifesting Huntington's Disease	Phase 1	Withdrawn	Jul 30, 2021	Dec 30, 2024 (estimated)